기업 정보 불러오는 중
Just reported
Q3 2026 results
From Labcorp's results release of 2026년 10월 28일; its quarterly report has since been filed.
Revenue
Actual
US$3.81B
+6.9% y/y
+2.1% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$3.22
+3.2% y/y
-12% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$402.1M
+1.4% y/y
-11% q/qGuided
—
No guide given
Company outlook
Full year 2026
- EPS, adjustedUS$18.30 – US$18.70Raised +1.0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.US$259.4BA+
IDXXIdexx Laboratories Inc.US$55.5BA+
IQVIQVIA Holdings Inc.US$43.7BA
ILMNIllumina, Inc.US$31.3BA+
DGXQuest Diagnostics IncUS$28.6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Diagnostic laboratory testing78%
- Biopharma laboratory services22%
매출 비중은 year ended 2025-12-31 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
경쟁 상대
무엇을 파는가6
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
3개 더 보기
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
누가 사는가6
- Physicians and medical practices order tests for patients and may receive the bills themselves or direct billing to patients or health plans.
- Hospitals and health systems use Labcorp for testing, including outreach laboratory services and tests they send to an outside laboratory.
- Health plans and managed care organizations pay for covered tests under negotiated fee schedules or per-member payment arrangements.
3개 더 보기
- Medicare and Medicaid pay for eligible tests under government fee schedules.
- Patients pay for tests when uninsured, for their share of an insured test, or when they order tests directly.
- Pharmaceutical, biotechnology, medical device and diagnostic companies, along with contract research organizations, buy laboratory services under contracts.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Diagnostic revenue depends on reimbursement rules, coverage decisions and negotiated payment rates from health plans and government programs.
- 2A portion of diagnostic revenue depends on collecting patient balances, including deductibles, coinsurance and bills for uninsured patients.
- 3Biopharma Laboratory Services depends in part on research and development spending by pharmaceutical, biotechnology and medical device companies.
- 4Laboratory work depends on qualified staff, laboratory facilities, supplies and third-party transportation and services.
잘못될 수 있는 일
- 1Changes to government or health-plan coverage and reimbursement, including changes affecting Medicaid or insurance exchanges, could reduce testing volumes or payments. The company has identified possible changes to Medicaid and the Affordable Care Act as a source of potential pressure on diagnostic testing.
- 2Patients account for a material portion of diagnostic receivables, and Labcorp may collect less than billed when patients cannot or will not pay their share.
- 3Reduced research and development spending, changes in pharmaceutical or medical-device regulation, or the loss or early termination of contracts could reduce demand for Biopharma Laboratory Services or leave Labcorp with contract costs it cannot recover.
Labcorp Holdings Inc. 소개
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
- 본사
- Burlington, North Carolina
- 설립
- 1978
- 상장 시장
- NYSE
- 회계연도 종료
- December 31
Labcorp Holdings Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
